Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for...
71 insider purchases on record · latest filing 2024-10-09.
Insiders have also filed 1 sale transaction at WINT.